Ambrx Biopharma Cayman, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2022 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2022 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $2.89M, a 53.6% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.25M, a 47.3% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.9M, a 874% increase from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $1.22M, a 33.5% decline from 2019.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $2.89M +$1.01M +53.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $1.94M +$288K +17.5% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q2 2022 $1.88M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $1.65M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.